CAR T cell immunotherapy, which uses a patient’s own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers, such as lymphoma and leukemia, ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

A new generation of CAR T cell therapy is bringing hope in the fight against cancer, targeting not only blood cancers but also solid tumors such as ovarian and breast cancer. Fraunhofer researchers ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric ...

The Vanderbilt-Ingram Cancer Center is helping pioneer a new treatment that reengineers T-cells so they seek and destroy cancer cells. Dr. Olalekan Oluwole, an oncologist, is helping spearhead an ...

“Your cancer has spread” is terrifying news to hear. But it’s unfortunately common for people with colorectal cancer. The cancer is the third most common tumor globally and accounted for 930,000 ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CART ...